IBTROZI FDA approval date

The FDA approved IBTROZI on 11 Jun 2025.

FDA approval date
11 Jun 2025

Drug identity has not yet been verified against registry records

Also recorded as TALETRECTINIB ADIPATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2025-06-11DayIBTROZIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA219713", "applicant_as_listed_by_fda": "NUVATION", "brand_names": ["IBTROZI"], "active_ingredients": ["TALETRECTINIB ADIPATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20250611", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026